A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.
10.4093/dmj.2014.38.4.261
- Author:
Chang Hee JUNG
1
;
Jung Eun JANG
;
Joong Yeol PARK
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jypark@amc.seoul.kr
- Publication Type:Review
- Keywords:
Canagliflozin;
Dapagliflozin;
Diabetes mellitus, type 2;
Glucosuria;
SGLT2 inhibitor
- MeSH:
Absorption;
Diabetes Mellitus, Type 2*;
Drug Therapy;
Glucose;
Homeostasis;
Humans;
Hypoglycemic Agents;
Insulin;
Kidney;
Prevalence;
Public Health;
Canagliflozin
- From:Diabetes & Metabolism Journal
2014;38(4):261-273
- CountryRepublic of Korea
- Language:English
-
Abstract:
Type 2 diabetes mellitus (T2DM) is a complex endocrine and metabolic disorder, and a major public health problem that is rapidly increasing in prevalence. Although a wide range of pharmacotherapies for glycemic control is now available, management of T2DM remains complex and challenging. The kidneys contribute immensely to glucose homeostasis by reabsorbing glucose from the glomerular filtrate. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents that inhibit glucose absorption from the kidney independent of insulin, offer a unique opportunity to improve the outcomes of patients with T2DM. In this review, we provide an overview of two globally-approved SGLT2 inhibitors, dapagliflozin and canagliflozin, and discuss their effects and safety. This information will help clinicians to decide whether these drugs will benefit their patients.
